Cetuximab: all 645 studies that test it
Page 4 of 7. Open to participants first (75), then studies with results posted, then the rest; newest registration first within each.
- Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesActive, not recruitingNCT05226871Phase 2
- A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingNCT05217446Phase 2
- FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRCCompletedNCT05217069Phase 2
- JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationActive, not recruitingNCT05194995Phase 1/2
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
- Cetuximab for the Treatment of Advanced Unresectable or Metastatic ChordomaActive, not recruitingNCT05041127Phase 2
- A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)CompletedNCT05040568Phase 1
- A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor TreatmentStatus unknownNCT04872634Phase 1/2
- Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRCCompletedNCT04835142Phase 3
- c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRIStatus unknownNCT04833036Phase 2
- Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)Active, not recruitingNCT04793958Phase 3
- Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal CancerCompletedNCT04790448Phase 1/2
- An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant TumorCompletedNCT04739111Phase 1
- Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLCWithdrawnNCT04648189Phase 2
- Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal CancerCompletedNCT04561336Phase 2
- Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver MetastasesStatus unknownNCT04525326Phase 3
- AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer PatientsCompletedNCT04513951Phase 2
- Cetuximab Re-challenge for Colorectal Cancer Liver MetastasisStatus unknownNCT04509635Phase 3
- TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
- Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnNCT04464967Phase 1/2
- CIML NK Cell in Head & Neck CancerCompletedNCT04290546Phase 1
- Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor FailureCompletedNCT04278092Phase 2
- Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal CancerActive, not recruitingNCT04262635Phase 3
- A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal CancerStatus unknownNCT04241731Phase 2
- Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.Active, not recruitingNCT04229459Phase 2
- Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRCCompletedNCT04224415Phase 2
- Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell CarcinomaTerminatedNCT04106362Phase 2
- sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCCCompletedNCT04091867Phase 1
- Intratumoral Microdosing of TAK-981 in Head and Neck CancerCompletedNCT04065555Early Phase 1
- FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRCActive, not recruitingNCT04034459Phase 2
- Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04017650Phase 1/2
- Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)Status unknownNCT03944252Phase 2
- A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic CancersTerminatedNCT03783403Phase 1
- Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)Status unknownNCT03727763Phase 2
- Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung CancerCompletedNCT03727724Phase 2
- Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CancerCompletedNCT03667482Phase 1
- Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary ResistanceStatus unknownNCT03666325Phase 2
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnNCT03647423Phase 1/2
- Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable CancerStatus unknownNCT03608046Phase 2
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnNCT03563170Phase 1/2
- Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal CancerTerminatedNCT03524820Phase 2
- Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell CarcinomaCompletedNCT03524326Phase 1
- Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03498378Phase 1
- EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck CancerCompletedNCT03494322Phase 2
- Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 StatusStatus unknownNCT03457896Phase 2
- Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody TrialTerminatedNCT03426371Phase 3
- PETACC-8 miR-31-3p and miR-31-5p Ancillary StudyCompletedNCT03362684Phase 3
- Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal CancerCompletedNCT03290937Phase 1
- HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03284502Phase 1
- CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal CancerCompletedNCT03206151Phase 3
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2
- Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy NetworkCompletedNCT03164655Phase 2
- Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT03126708Phase 2
- NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT03109158Phase 1/2
- Durvalumab, Cetuximab and Radiotherapy in Head Neck CancerStatus unknownNCT03051906Phase 1/2
- Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver MetastasisCompletedNCT03031444Phase 2/3
- Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell CarcinomaActive, not recruitingNCT03024489Phase 1/2
- Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)Active, not recruitingNCT02999087Phase 3
- Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)CompletedNCT02938273Phase 1
- Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus CetuximabCompletedNCT02934529Phase 3
- Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With CetuximabCompletedNCT02845999Phase 1
- Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN LossTerminatedNCT02822482Phase 1/2
- Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck CancerTerminatedNCT02817113Phase 1
- Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant ChemotherapyStatus unknownNCT02753140Phase 2
- Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerCompletedNCT02716311Phase 2
- CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)Status unknownNCT02675946Phase 1
- Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal CancerStatus unknownNCT02636088Phase 2
- Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Phase 3
- Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal CancerWithdrawnNCT02630420Phase 1
- A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)CompletedNCT02627274Phase 1
- Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and NeckStatus unknownNCT02624128Phase 2
- Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal CancerWithdrawnNCT02573220Phase 1
- A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus BevacizumabStatus unknownNCT02515734Phase 2
- Reactivating NK Cells in Treating Refractory Head and Neck CancerStatus unknownNCT02507154Phase 1/2
- Novel Treatment Option for Neuropathic PainCompletedNCT02490436Phase 2
- Erbitux MEtastatic Colorectal Cancer Strategy StudyCompletedNCT02484833Phase 3
- Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and NeckTerminatedNCT02438995Phase 1
- Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)CompletedNCT02404935Phase 2
- Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II StudyTerminatedNCT02316496Phase 2
- Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell CarcinomaWithdrawnNCT02298595Phase 1/2
- Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).Status unknownNCT02296203Phase 2
- Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)CompletedNCT02282371Phase 1
- Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway MutationsCompletedNCT02278133Phase 1/2
- Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT02277197Phase 1
- Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT02270814Phase 2
- Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid TumorsCompletedNCT02215720Phase 1
- Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab TherapyTerminatedNCT02205398Phase 1
- Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma PatientsWithdrawnNCT02143622Phase 1/2
- N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic TherapyCompletedNCT02142036Phase 2
- Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT02123381Phase 2
- Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck CancerCompletedNCT02110082Phase 1
- Regorafenib and Cetuximab in Patients With Advanced MalignancyCompletedNCT02095054Phase 1
- Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal CancerStatus unknownNCT02071069Phase 2
- FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal CancerCompletedNCT02063529Phase 2
- A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and NeckStatus unknownNCT02054442Phase 1/2
- Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and NeckTerminatedNCT02015650Phase 4
- Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)WithdrawnNCT02014831Phase 2
- Safety and Pharmacokinetics of Regorafenib and Cetuximab in CombinationCompletedNCT01973868Phase 1
- A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.CompletedNCT01969877Phase 3